Loading...

Coeptis Therapeutics Holdings, Inc.

COEPW•NASDAQ
HealthcareBiotechnology
$0.03
$0.01(70.45%)

Coeptis Therapeutics Holdings, Inc. (COEPW) Stock Overview

Explore Coeptis Therapeutics Holdings, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for COEPWStats details for COEPW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for COEPWAnalyst Recommendations details for COEPW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.

CEO

Mr. David Mehalick

Employees

4

Headquarters

105 Bradford Road, Wexford, PA

Founded

1970

Frequently Asked Questions